Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,716.09
(
0.25%
)
US TECH 100
24,132.40
(
0.00%
)
Dow Jones
46,993.26
(
0.10%
)
Brent Oil
99.76
(
-0.88%
)
Bitcoin
73,936.84
(
-0.01%
)
News Focus
News Focus
Post# of 257253
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122793
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 132914

Thursday, 02/09/2012 3:54:27 PM

Thursday, February 09, 2012 3:54:27 PM

Post# of 257253
Bayer expects Xarelto approval in China for AF/stroke prevention during 2013:

http://www.reuters.com/article/2012/02/09/healthcare-bayer-china-idUSL4E8D90Z920120209

Xarelto has already won approvals from the United States, European Union, Malaysia and Japan for use to prevent stroke in patients with atrial fibrillation, or an irregular heartbeat. Approvals from other countries are expected in coming months.

…One out of every five deaths in China is now due to stroke…

A remarkable figure; however, not all stroke deaths are related to attril fib, so the above overstates the addressable market for Xarelto to some degree.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now